^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    WTX212

    i
    Other names: WTX212, WTX212A, engineered red blood cell, Erythrocyte-αPD-1 conjugate, WTX-212, WTX-212A, WTX 212, WTX 212A
    Associations

    News

    Trials
    Company:
    Westlake Therap
    Drug class:
    PD1 inhibitor, Immunomodulator
    Related drugs:
    Associations

    News

    Trials
    4ms
    Safety, Tolerability and Preliminary Efficacy of Erythrocyte-αPD-1 Conjugate in Patients With Advanced Malignancies (clinicaltrials.gov)
    P1, N=39, Not yet recruiting, Zhejiang Provincial People's Hospital
    New P1 trial • Metastases
    |
    WTX212
    4ms
    FIH: Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies (clinicaltrials.gov)
    P1, N=30, Recruiting, Westlake Therapeutics | Trial completion date: Jul 2024 --> Jul 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    WTX212
    6ms
    A Dose Escalation and Dose Expansion Trial of WTX212A in the Treatment of Patients With Advanced Malignant Tumors (clinicaltrials.gov)
    P1, N=44, Recruiting, Zhejiang University | Not yet recruiting --> Recruiting
    Enrollment open • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    WTX212
    8ms
    Reboot-105: WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody (clinicaltrials.gov)
    P1, N=20, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    WTX212
    1year
    A Exploratory Trial of WTX212A Injection in the Treatment of Patients With Advanced Lung Cancer (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P1 trial • Metastases
    |
    WTX212
    1year
    A Dose Escalation and Dose Expansion Trial of WTX212A in the Treatment of Patients With Advanced Malignant Tumors (clinicaltrials.gov)
    P1, N=44, Not yet recruiting, Zhejiang University
    New P1 trial • Metastases
    |
    PD-1 (Programmed cell death 1)
    |
    WTX212